Satellos Bioscience (MSLE) Cash & Equivalents (2023 - 2026)

Satellos Bioscience (MSLE) has 4 years of Cash & Equivalents data on file, last reported at $18.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $18.7 million in Q1 2026; TTM through Mar 2026 was $18.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $9.8 million, down 75.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $18.7 million, up from $9.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MSLE reached as high as $41.3 million in Q4 2024 and fell as low as $9.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $21.5 million across 4 years, with a median of $17.5 million in 2023.
• Across the five-year window, Cash & Equivalents jumped 154.64% in 2024 and slumped 76.25% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $16.2 million in 2023, then soared by 154.64% to $41.3 million in 2024, then slumped by 76.25% to $9.8 million in 2025, then jumped by 90.71% to $18.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $18.7 million in Q1 2026, $9.8 million in Q4 2025, and $41.3 million in Q4 2024.